Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Typhoid-Paratyphoid Vaccines: Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.Vaccines, Attenuated: Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Combined: Two or more vaccines in a single dosage form.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.Rotavirus Vaccines: Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Tuberculosis Vaccines: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Chickenpox Vaccine: A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.Diphtheria-Tetanus-Pertussis Vaccine: A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.Mumps Vaccine: Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.Hepatitis A Vaccines: Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).Immunization Schedule: Schedule giving optimum times usually for primary and/or secondary immunization.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Measles-Mumps-Rubella Vaccine: A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.Streptococcal Vaccines: Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.Dengue Vaccines: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.Vaccines, Virosome: Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Allergy and Immunology: A medical specialty concerned with the hypersensitivity of the individual to foreign substances and protection from the resultant infection or disorder.Pyrogens: Substances capable of increasing BODY TEMPERATURE and cause FEVER and may be used for FEVER THERAPY. They may be of microbial origin, often POLYSACCHARIDES, and may contaminate distilled water.History, 19th Century: Time period from 1801 through 1900 of the common era.Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.Clinical Trials, Phase I as Topic: Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.Immunity, Active: Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.Scarlet Fever: Infection with group A streptococci that is characterized by tonsillitis and pharyngitis. An erythematous rash is commonly present.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Streptococcus pyogenes: A species of gram-positive, coccoid bacteria isolated from skin lesions, blood, inflammatory exudates, and the upper respiratory tract of humans. It is a group A hemolytic Streptococcus that can cause SCARLET FEVER and RHEUMATIC FEVER.Skin UlcerSicilyRheumatic Fever: A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin.Parrots: BIRDS of the large family Psittacidae, widely distributed in tropical regions and having a distinctive stout, curved hooked bill. The family includes LOVEBIRDS; AMAZON PARROTS; conures; PARAKEETS; and many other kinds of parrots.
Ellis, Ronald W.; Brodeur, Bernard R. (2012). New Bacterial Vaccines. Springer Science & Business Media. p. 158. ISBN ... Adams, James (2013). Emergency Medicine Clinical Essentials. Saunders. pp. 149-158. "Initiative for Vaccine Research (IVR)- ... The vaccine approach has a greater likelihood of effectively preventing group A streptococcal infections because vaccine ... There have been several attempts to create a vaccine in the past few decades. These vaccines, which are still in the ...
Development and Clinical Uses of Haemophilus b Vaccine. Marcel Dekker, New York, 1994;329-338. Gupta RK, Rost BE, Relyveld E, ... Bacterial Vaccines. New York: Praeger, 1987. Siber GR. Special Lecture: importance of IgG subclasses and genetic factors in ... "Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults". Vaccine. 25 (33): 6164-6. doi:10.1016/j.vaccine ... Vaccine-type and non-vaccine type pneumococci after administration of 9valent CRM 197 conjugate pneumococcal vaccine (Pnc CRM9 ...
Adams, James (2013). Emergency Medicine Clinical Essentials. Saunders. pp. 149-158.. *^ "Initiative for Vaccine Research (IVR)- ... Ellis, Ronald W.; Brodeur, Bernard R. (2012). New Bacterial Vaccines. Springer Science & Business Media. p. 158. ISBN ... Ferri, Fred (2018). Ferri's Clinical Advisor 2018. Elsevier. p. 1143.. *^ a b c Goldman, Lee; Schafer, Andrew (2016). Goldman- ... The vaccine approach has more potential to do so since vaccine formulations can target multiple subtypes of the bacteria.[13] A ...
... molecular and clinical aspects; Molecular and Clinical Aspects of Bacterial Vaccine Development; and Medical Microbiology. He ... From 1988 to 2014, Ala'Aldeen has worked on pathogenesis, molecular epidemiology and vaccine development of various bacterial ... He was appointed as a clinical academic in the University Hospital of Nottingham in 1992 and became Professor of clinical ... Screening of neisserial vaccine candidates and vaccines against pathogenic ... - Google Patents Journal of Medical Microbiology ...
Vaccines against bacterial meningitis (PDF). British Medical Bulletin. 2004, 72 (1): 65-81. PMID 15802609. doi:10.1093/bmb/ ... Prospects for vaccine prevention of meningococcal infection (PDF). Clinical Microbiology Reviews. 2006年1月, 19 (1): 142-64. PMC ... Practice guidelines for the management of bacterial meningitis (PDF). Clinical Infectious Diseases. 2004年11月, 39 (9): 1267-84. ... 用肺炎球菌聯合疫苗(英語:Pneumococcal conjugate vaccine)(PCV)--一種能預防這種病原中七種常見血清
Currently, no licensed vaccine targeting Shigella exists. Several vaccine candidates for Shigella are in various stages of ... Shigellosis is a type of diarrhea caused by a bacterial infection with Shigella. Symptoms generally start one to two days after ... Katzung, Bertram G. (2007). Basic and Clinical Pharmacology. New York, NY: McGraw Hill Medical. p. 733. ISBN 978-0-07-145153-6 ... "Vaccine Research And Development: New strategies for accelerating Shigella vaccine development" (PDF). Weekly Epidemiological ...
... molecular and clinical aspects; Molecular and Clinical Aspects of Bacterial Vaccine Development; and Medical Microbiology. He ... From 1988 to 2014, Ala'Aldeen has worked on pathogenesis, molecular epidemiology and vaccine development of various bacterial ... Patent US6861507 - Screening of neisserial vaccine candidates and vaccines against pathogenic ... - Google Patents ... He was also the Founding Director of the MSc course in Clinical Microbiology in Nottingham University [5] He was seconded to ...
This vaccine is manufactured in Australia and a closely similar vaccine is manufactured in Cuba. Walker, M.D. (2017) Ticks on ... Against Babesia protozoa are imidocarb and diminazine, both of which can be used to treat patent clinical infections. Against ... Antibiotics with efficacy against bacterial pathogens transmitted by ticks include: tetracycline, penicillin, and doxicycline. ... Vaccines are often highly effective, but the live parasite vaccines have problems of potential contamination with other ...
Clinical signs are most commonly seen in birds between the ages of 1-8 weeks old. Systemic infection is most common, producing ... Both a live and inactivated vaccines are available to control the disease. Good husbandry is also an essential part of disease ... This diagnosis can be confirmed using laboratory tests such as bacterial culture, PCR and ELISA. Antibiotics are the treatment ... The signs seen on clinical exam and postmortem are normally sufficient to make a presumptive diagnosis. ...
Lee CJ, Lee LH, Koizumi K. (2002) Polysaccharide Vaccines for Prevention of Encapsulated Pseudomonas Aueroginosa Bacterial ... Vinuesa C, de Lucas C, Cook M (2001). "Clinical implications of the specialised B cell response to polysaccharide encapsulated ... These vaccines can be remembered with the mnemonic: SHiN. Alternatively they can be called the NHS bacteria, as in National ... Conjugate vaccines are used to produce an immune response in these cases. Patients with complement deficiency are at risk of ...
... is a live attenuated Listeria cancer vaccine that is under investigation (2008) and has entered clinical trials. It ... Note: Lovaxin C has been renamed ADXS11-001 The bacterial genus Listeria includes intracellular pathogenes able to induce a ... The concept has been tested in a mouse model where the vaccine led to regression of renal and colon cancer. In phase I/II ... The vaccine is derived from bioengineered Listeria monocytogenes that have been attenuated and produce a tumor antigen. Lovaxin ...
... potentially improving clinical outcomes. Specific examples include: 16s rRNA sequencing to provide bacterial identifications ... Molecular microbiology techniques are currently being used in the development of new genetically engineered vaccines, in ... Bacterial viruses, or bacteriophages, are estimated to be the most widely distributed and diverse entities in the biosphere. ... The complete genome sequence for a large number of bacterial species is now available. A list of sequenced prokaryotic genomes ...
She is best known for her development of the vaccine against bacterial meningitis (Haemophilus influenzae type B (Hib)) with ... Albert Lasker Clinical Medical Research Award in 1996 for "groundbreaking work and bold, visionary and imaginative leadership ... The two became an inseparable research team, "dedicated to developing vaccines to protect children from bacterial diseases." ... Rachel Schneerson is best known for her work on the vaccine for Haemophilus influenza type B, or Hib. Prior to the vaccine's ...
A presumptive diagnosis can be made based in the history and clinical signs, but definitive diagnosis requires bacterial ... Vaccines can also be used in the treatment and prevention of disease. Management factors such as maintaining water quality and ... Enteric redmouth disease, or simply redmouth disease is a bacterial infection of freshwater and marine fish caused by the ...
bacterial, on Oxford Dictionaries Moloney, Mark G. (1 August 2016). "Natural Products as a Source for Novel Antibiotics". ... Antibiotics are screened for any negative effects before their approval for clinical use, and are usually considered safe and ... Alita A. Miller; Paul F. Miller (2011). "Current Strategies for Antibacterial Vaccine development". Emerging Trends in ... Marquez B (2005). "Bacterial efflux systems and efflux pumps inhibitors". Biochimie. 87 (12): 1137-47. doi:10.1016/j.biochi. ...
... plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to U.S. Food and Drug ... Status of Vaccine Research and Development of Vaccines for Schistosomiasis Official website. ... The company's first goal was to perfect a vaccine for fish breeding through genetic engineering. 1987: Eurogentec started to ... As of September 2014 Eurogentec Biologics was developing a vaccine against bilharziosis called Bilhvax in partnership with ...
Pre-clinical investigation of vaccines for Enterotoxigenic E. coli, Shigella, Campylobacter jejuni, Dengue, malaria in an Aotus ... and bacterial illnesses like traveler's diarrhea (ETEC, campylobacter, shigella). to augment public health and military medical ... Navy Research timeline first Description of Iquitos virus First clinical description of Mayaro virus Center for Strategic and ... Implementation of NAMRU-6's mission is via threefold means: to investigate prophylactic agents such as vaccines and ...
Anthrax vaccine. Pasteur publicly claimed his success in developing the anthrax vaccine in 1881.[93] However, his admirer- ... "Clinical Microbiology and Infection. 18 (s5): 1-6. doi:10.1111/j.1469-0691.2012.03945.x.. ... He is best known to the general public for his invention of the technique of treating milk and wine to stop bacterial ... After developing the rabies vaccine, Pasteur proposed an institute for the vaccine.[136] In 1887, fundraising for the Pasteur ...
WHO (1999). "Pneumococcal vaccines. WHO position paper". Wkly. Epidemiol. Rec. 74 (23): 177-83. PMID 10437429. Hoare, Z; Lim, ... Anevlavis S; Bouros D (February 2010). "Community acquired bacterial pneumonia". Expert Opin Pharmacother. 11 (3): 361-74. PMID ... WS (2006-05-06). "Pneumonia: update on diagnosis and management.". BMJ (Clinical research ed.). 332 (7549): 1077-9. PMC 1458569 ... being caused by the bacteria for which an effective vaccine is available. In the United Kingdom, the annual incidence rate of ...
... were in clinical trials for the prevention of harmful effects caused by gram-negative bacterial infections. However, trials ... On the other hand, modified versions of lipid A can be used as components of vaccines (adjuvants) to improve their effect. ... When present in the body at high concentrations during a gram-negative bacterial infection, it may cause shock and death by an ... 2010). "Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant". PLoS ONE. 6 ...
Currently, no vaccine is known in the US against M. catarrhalis infection. It is a significant cause of respiratory tract ... Additionally, it causes bacterial pneumonia, especially in adults with a compromised immune system. It has also been known to ... Manual of Clinical Microbiology, 10th edition. James Versalovic, copyright 2012 ASM press. Type strain of Moraxella catarrhalis ... The great majority of clinical isolates of this organism produce beta-lactamases, so are resistant to penicillin. Resistance to ...
These usually resolve within four to seven days, but secondary bacterial infections can cause the persistence of clinical signs ... There is a vaccine for FHV-1 available (ATCvet code: QI06AA08 (WHO), plus various combination vaccines), but although it limits ... and predispose these cats to chronic bacterial infections. Diagnosis of FVR is usually by clinical signs, especially corneal ... Studies have shown a duration of immunity of this vaccine to be at least three years. The use of serology to demonstrate ...
As the three leading causes of bacterial meningitis in childhood are vaccine preventable, the regular use of conjugate vaccines ... ". "European Society of Clinical Microbiology and Infectious Diseases". "Czech National Institute of Public Health". "National ... Sequelae Due to Bacterial Meningitis among African Children: A Systematic Literature Review, and Bacterial Infections in ... is a project of the Sabin Vaccine Institute and is composed of global experts in infectious diseases and vaccines. Established ...
1 R21 AI083381-01 Oral Vaccine Platform for Class A Bacterial Agents, NIH, 1 R01 AI084952 Generation and Characterization of ... "Foundation for Clinical Research in Inflammatory Bowel Disease". Retrieved September 21, 2011. "The Crohn's & Colitis ... Mayer was elected to the American Society for Clinical Investigation in 1991 and the Association of American Physicians in 1997 ... Sigma Xi (Science Honor Society), 1972 Alpha Omega Alpha, 1975 and 1976 Mosby Award for Clinical Excellence, 1976 Irma T. ...
... best known for his development of the vaccine against bacterial meningitis (Haemophilus influenzae type B (Hib)) with his ... Robbins is a recipient of the 1996 Albert Lasker Award for Clinical Medical Research, the Pasteur Award from the World Health ... Bacterial meningitis is the leading cause of acquired mental retardation in children. ... Sabin Gold Medal in 2001 which he received for playing a major role in the development of Hib conjugate vaccine that is now ...
Vaccine[edit]. Main article: Pneumococcal vaccine. Due to the importance of disease caused by S. pneumoniae, several vaccines ... Natural bacterial transformation involves the transfer of DNA from one bacterium to another through the surrounding medium. ... Diagnosis is generally made based on clinical suspicion along with a positive culture from a sample from virtually any place in ... "Pneumococcal vaccines WHO position paper--2012" (PDF). Wkly Epidemiol Rec. 87 (14): 129-44. Apr 6, 2012. PMID 24340399.. ...
Adams, James (2013). Emergency Medicine Clinical Essentials. Saunders. pp. 149-158.. *^ "Initiative for Vaccine Research (IVR)- ... Ellis, Ronald W.; Brodeur, Bernard R. (2012). New Bacterial Vaccines. Springer Science & Business Media. p. 158. ISBN ... Ferri, Fred (2018). Ferris Clinical Advisor 2018. Elsevier. p. 1143.. *^ a b c Goldman, Lee; Schafer, Andrew (2016). Goldman- ... The vaccine approach has more potential to do so since vaccine formulations can target multiple subtypes of the bacteria.[13] A ...
... indicate that a live attenuated enterotoxigenic Escherichia coli vaccine candidate, given in combination with a novel adjuvant ... Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea Vaccine/adjuvant combination against ... Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea. PATH. Funder. The research was ... Currently, no licensed vaccines targeting ETEC exist. The study was conducted by PATH in collaboration with Johns Hopkins ...
The vaccine/adjuvant combination was also protective against severe ETEC diarrhea in this model with a protective efficacy of ... This represents the first efficacy data for this vaccine/adjuvant combination, which was 58.5 percent efficacious in protecting ... vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease. ... Clinical Results Indicate Vaccine Candidate is Highly Efficacious Against Bacterial Diarrhea. October 27, 2014 ...
Thank you for sharing this Clinical and Vaccine Immunology article.. NOTE: We request your email address only to inform the ... Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology. ... Your Name) has forwarded a page to you from Clinical and Vaccine Immunology ... Clinical and Diagnostic Laboratory Immunology Mar 2002, 9 (2) 403-411; DOI: 10.1128/CDLI.9.2.403-411.2002 ...
Thank you for sharing this Clinical and Vaccine Immunology article.. NOTE: We request your email address only to inform the ... Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology. ... Your Name) has forwarded a page to you from Clinical and Vaccine Immunology ... potentially reducing bacterial numbers nonspecifically and therefore limiting bacterial colonization (9, 11, 13). Some ...
Cancer Therapy: Clinical Phase I Clinical Trial of Mixed Bacterial Vaccine (Coleys Toxins) in Patients with NY-ESO-1 ... Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients. Med Oncol Tumor Pharmacother 1993;10: ... Phase I Clinical Trial of Mixed Bacterial Vaccine (Coleys Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological ... Phase I Clinical Trial of Mixed Bacterial Vaccine (Coleys Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological ...
International Conference on Clinical Microbiology, Virology and Infectious Diseases September 10-12, 2018 Bucharest, Romania ... Vaccines derived from bacterium is called as bacterial vaccine and from virus is as viral vaccine. The subsequent vaccine ... Bacterial and Viral Vaccines. Immunization(vaccination) can be discrete as active immunity formed by vaccine. It is resistance ... Related Conference of Bacterial and Viral Vaccines. March 1-2, 2018. 5th International congress on Infectious Diseases. Berlin ...
Phase I clinical trial of mixed bacterial vaccine (Coleys toxins) in patients with NY-ESO-1 expressing cancers: Immunological ... Phase I clinical trial of mixed bacterial vaccine (Coleys toxins) in patients with NY-ESO-1 expressing cancers: Immunological ... effects and clinical activity. Abstract:. Purpose: Mixed bacterial vaccine (MBV, Coleys toxins) is a historical, vaguely ... clinical article; treatment response; unclassified drug; human cell; drug safety; side effect; cancer staging; outcome ...
Studies on the clinical application of pneumococcal vaccine. Distribution of Streptococcus pneumoniae in Japan].. [Article in ...
Clinical Evaluation. Additional relevant MeSH terms: Bacterial Infections. Tetanus. Clostridium Infections. Gram-Positive ... The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that ... Bacterial Infections Group B Streptococcus Biological: GBS III-TT-SSI Biological: GBS III-TT-MPHL Phase 1 ... Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines. The safety and scientific validity of this ...
Bacterial Vaccines. *Europe/epidemiology. *Francisella tularensis/classification. *Francisella tularensis/pathogenicity*. * ... Department of Clinical Bacteriology, Clinical Microbiology, Umeå University, SE-901 85 Umeå, Sweden. [email protected] ... Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations.. Sjöstedt A1.. Author information. 1. ... This article summarizes, predominantly with a historical perspective, the epidemiology and clinical manifestations of tularemia ...
Gram-Positive Bacterial Infections. Bacterial Infections. Vaccines. Isoniazid. Immunologic Factors. Physiological Effects of ... placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010 Jan 22;28(4):1106-16 ... Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following ... The vaccine has been designed to be used against Latent Tuberculosis Infection as a therapeutic vaccine after 1-month of ...
... promising Shigella vaccine candidates have been selected based on their ability to confer resistance against experimental ... Bacterial Vaccines / administration & dosage* * Bacterial Vaccines / adverse effects * Bacterial Vaccines / immunology * ... A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical ... In the absence of a definitive immunologic correlate of protection against shigellosis, promising Shigella vaccine candidates ...
Bacterial Vaccines* * Bordetella pertussis / chemistry* * Bordetella pertussis / immunology* * Bordetella pertussis / isolation ... We compared here the LPS structures of four clinical isolates with that of the vaccine strain BP 1414. All physico-chemical ... Comparison of lipopolysaccharide structures of Bordetella pertussis clinical isolates from pre- and post-vaccine era Carbohydr ... These results are rendering these major antigens good potential vaccine components. Molecular modeling of this conserved LPS ...
Zika Vaccine Shows Promise in Early Clinical Trial. By Ashley P. Taylor , October 5, 2017 ... DNA-Delivered Antibodies Fight Off Lethal Bacterial Infection. By Catherine Offord , October 3, 2017 ... In humans, the DNA vaccine elicited the production of antibodies, which then protected mice from Zika infection. ...
Zika Vaccine Shows Promise in Early Clinical Trial. By Ashley P. Taylor , October 5, 2017 ... DNA-Delivered Antibodies Fight Off Lethal Bacterial Infection. By Catherine Offord , October 3, 2017 ... The vaccine shows better-than-expected effectiveness against the most common and most virulent strain of influenza in children ... Daily News Stem Cell Vaccine Protects Mice From Cancer Stem cells and cancer cells have enough molecular similarities that the ...
BMJ (clinical research ed.) 2008; 336(7634); 36-40.. *Segal S, Pollard AJ. Vaccines against bacterial meningitis. Brit Med Bull ... ︉ Meningitis B vaccine. From September 2015 a new Meningitis B or Men B vaccine (Bexsero) will be offered to babies at 2, 4 and ... ︉ Meningitis C vaccine. The meningitis C vaccine (Menjugate orNeisVac-C ) is made from a small inactivated part of the ... ︉ Hib vaccine. The Hib vaccine is made from a small inactivated part of the Haemophilus influenzae type B bacteria and works in ...
... for Pneumococcal Vaccines for Adults aged 65 years or older. ... CDC vaccine recommendations of ACIP as published in policy ... Clinical Infectious Diseases. July 15, 2009 2009;49(2):241-248.. * US Food and Drug Administration. Vaccines and Related ... Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network. Unpublished 2013 ABCs Data on Streptococcus ... The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 ...
Develop new bacterial and viral vaccines to reduce the incidence of acute bacterial sinusitis. ... IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72- ... Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. Ellen ... 13-valent pneumococcal conjugate vaccine. RABS - recurrent acute bacterial sinusitis. RCT - randomized controlled trial. URI - ...
Mycology and Bacterial Diseases Conference scheduled on July 16-17, 2020 in July 2020 in Stockholm is for the researchers, ... Bacterial pathogenesis. Oral vaccine platform for class a bacterial agents. Bacterial defense phagocytosis, immune responses. ... Clinical Bacteriology, Mycology and Bacterial Diseases. ICCBMBD 2020: 14. International Conference on Clinical Bacteriology, ... Bacterial morphology and metabolism. Bacterial clinical studies. Bacteria in blood for transfusion. Human aeromonas infections ...
... molecular pathogenesis of bacterial disease; clinical microbiology and case studies in infectious diseases, environmental ... His work in immunology, culminating in the development of the HPV vaccine against cervical cancer, earned him the titles of the ... Jean-Paul Latge Jean-Paul Latge has led a group of scientists over the past decade with research and clinical interests on ... Ralph A Tripp Ralph Tripp is a Professor and Georgia Research Alliance Chair in Vaccine and Therapeutic Studies in the ...
... molecular and clinical aspects; Molecular and Clinical Aspects of Bacterial Vaccine Development; and Medical Microbiology. He ... From 1988 to 2014, AlaAldeen has worked on pathogenesis, molecular epidemiology and vaccine development of various bacterial ... Patent US6861507 - Screening of neisserial vaccine candidates and vaccines against pathogenic ... - Google Patents ... He was also the Founding Director of the MSc course in Clinical Microbiology in Nottingham University [5] He was seconded to ...
Obtain bacterial culture and Gram stain of tracheal secretions and blood cultures in patients with suspected bacterial ... Article Trending Clinical Topic: Flu Vaccine Recommendations * 2001 /viewarticle/918397 News News Reduce Measles Exposure in ... Obtain bacterial culture and Gram stain of tracheal secretions and blood cultures in patients with suspected bacterial ... Drugs & Diseases , Pediatrics: General Medicine , Bacterial Tracheitis Q&A What is the role of lab testing in the workup of ...
60 days old with fever and confirmed viral infections are at a lower risk for serious bacterial infections compared to infants ... Herpes Zoster Recombinant Vaccine Seems Most Effective However, adjuvant recombinant subunit vaccine tied to more injection ... "However, the non-negligible 3.7% rate of serious bacterial infections occurrence, including the 1.0% rate of invasive bacterial ... Clinical Advisor Return To Top ClinicalAdvisor.com is for nurse practitioners and physician assistants, offering the latest ...
"Conjugate vaccines". Clinical and Experimental Immunology. 119 (1): 1-3. doi:10.1046/j.1365-2249.2000.01109.x. PMC 1905528 ... They also exclude bacterial viruses and most hydrophobic toxic materials such as detergents.[citation needed] Immunity to one ... The bacterial capsule is a very large structure of many bacteria.[1] It is a polysaccharide layer that lies outside the cell ... A bacterial capsule has a semi-ridged border that follows the contour of the cell. The capsule excludes India Ink when dyed. A ...
  • Washington, DC, October 27, 2014--New results from a safety and immunogenicity study, which included a challenge phase to test efficacy, indicate that a live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate, given in combination with a novel adjuvant, provided significant protection against disease. (eurekalert.org)
  • This represents the first efficacy data for this vaccine/adjuvant combination, which was 58.5 percent efficacious in protecting against diarrhea of any severity using a highly rigorous ETEC human challenge model. (eurekalert.org)
  • The vaccine/adjuvant combination was also protective against severe ETEC diarrhea in this model with a protective efficacy of 65.9 percent. (eurekalert.org)
  • But like all disease interventions targeted at pathogen fitness, drugs and vaccines may drive pathogen evolution that undermines their efficacy, threatening the sustainability of medical and agricultural gains. (pnas.org)
  • Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. (ajtmh.org)
  • A Phase 3, Multicenter, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis. (centerwatch.com)
  • The Primary Objective if this study is to evaluate the efficacy of SHP640 based on clinical resolution (Defined as absence of bulbar conjunctival injection and ocular conjunctival discharge) compared with placebo in the treatment of subject with Bacterial Conjunctivitis in the study at Visit 3(Day5). (centerwatch.com)
  • In a few cases, even therapeutic efficacy of DC-based tumor vaccines was reported, leading to rejection of established tumors and lung metastases. (jimmunol.org)
  • Laudable as these efforts have been in producing vaccines with acceptable safety and tolerability, they failed to deliver on efficacy because of two shortcomings. (scidev.net)
  • To expect a whopping vaccine efficacy with single antigen vaccines is a pipe dream. (scidev.net)
  • Vaccine efficacy. (cdc.gov)
  • Numerous studies have demonstrated the immunogenicity and clinical efficacy of the A and C vaccines. (cdc.gov)
  • The serogroup A vaccine has been shown to have a clinical efficacy of 85%-95% and to be of use in controlling epidemics. (cdc.gov)
  • A similar level of clinical efficacy has been demonstrated for the serogroup C vaccine, both in American military recruits and in an epidemic. (cdc.gov)
  • Questions remain regarding how nontraditional products should be tested for safety and efficacy, and how they could be used appropriately in the clinical setting. (pewtrusts.org)
  • Vaccine-induced protection from Mycobacterium tuberculosis is dependent, at least in part, on a robust Th1 response, yet little is known of the ability of TB vaccines to induce other T-cell subsets which may influence vaccine efficacy. (semanticscholar.org)
  • in stage 2, we tested the efficacy of the gmDC vaccine for 12 acute myeloid leukemia (AML) patients with early molecular relapse. (jci.org)
  • All vaccines licensed for use in the United States undergo a rigorous process to test for both safety and efficacy. (nih.gov)
  • Once in use, vaccines continue to be monitored for safety and efficacy by the Food and Drug Administration and the Centers for Disease Control and Prevention. (nih.gov)
  • In addition, the federal government has numerous checks and balances in place to monitor the safety and efficacy of vaccines and to ensure that recommendations about immunization practices and procedures reflect the best available science. (nih.gov)
  • They did note whether trials were carried out under good clinical practice, whether an intention-to-treat (ITT) analysis had been performed, and if analysis had been per protocol. (york.ac.uk)
  • Three trials were reported as performed under good clinical practice. (york.ac.uk)
  • There are outcome measures that have been successfully incorporated in large clinical trials and the design and outcomes of these trials can be used to plan future clinical investigations in COPD. (omicsonline.org)
  • Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials? (semanticscholar.org)
  • Given the recent deadly outbreak of Marburg virus in Uganda, there is a critical need to develop a safe and effective vaccine which has the potential to protect our soldiers and the public from this serious threat," said Army Lt. Col. Melinda Hamer, Chief of the WRAIR Clinical Trials Center in Silver Spring, Maryland, where the trial is being conducted. (health.mil)
  • Universal, or cross-protective, vaccines - so named for their effectiveness against several flu strains - are being developed in various labs worldwide and some are already in clinical trials. (healthcanal.com)
  • They combined the latest information out of these vaccine trials, and the very latest and best models of influenza virus evolution and epidemiology. (healthcanal.com)
  • Several randomised clinical trials are in progress. (southampton.ac.uk)
  • We are active participants in the AIDS Clinical Trials Group (ACTG) and the HIV Vaccine Trials Network (HVTN). (brighamandwomens.org)
  • Validated biomarkers or correlates can guide vaccine development from the outset, winnowing out duds before they reach expensive clinical trials. (scidev.net)
  • Otherwise, clinical trials become hugely expensive exercises in trial and error. (scidev.net)
  • The way forward must start by mining clinical materials and information from the RV144, RTS,S/AS01, MVA85A and other trials for valuable insights about vaccine-induced protective immunity. (scidev.net)
  • and phase I-III clinical trials of antibiotics, antivirals, antifungals, and biologic-response modifiers. (rchsd.org)
  • Regulators approved the vaccine based on four clinical trials enrolling nearly 3,800 patients. (foxnews.com)
  • Edwards , through an international nonprofit he established called Medicine in Need, or MEND, is preparing to move the first inhalable TB vaccine candidate into clinical trials within the next six months, he says. (xconomy.com)
  • Plus, since it's an adapted form of an 80-year-old TB vaccine that's given to hundreds of millions of infants every year, its raw material is available for pennies a dose, and might be able to advance through clinical trials faster than other candidates that might need more testing, Edwards says. (xconomy.com)
  • We continue to advance our therapeutic mRNA-based (RNActive®) cancer immunotherapy for prostate cancer and lung cancer for which we are currently in clinical trials, and we are working to identify and develop other cancer immunotherapy candidates. (medgadget.com)
  • Of the 32 nontraditional products in development, seven were in Phase 1 clinical trials, 21 were in Phase 2 clinical trials, three were in Phase 3 clinical trials, and one was recently approved. (pewtrusts.org)
  • Safety testing is an integral part of every vaccine development stage-from lab studies to clinical trials to post-licensure evaluation. (nih.gov)
  • Scientists at the center conduct basic research on microbes and the immune system's response to them, design candidate vaccines, and, with their collaborators, test the most promising vaccines in preclinical and clinical trials. (nih.gov)
  • In 1999, NIAID created the HIV Vaccine Trials Network (HVTN), a collaboration of investigators in the United States and abroad that tests candidate HIV vaccines in clinical trials. (nih.gov)
  • aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Clinical Bacteriology, Mycology and Bacterial Diseases. (waset.org)
  • Also, high quality research contributions describing original and unpublished results of conceptual, constructive, empirical, experimental, or theoretical work in all areas of Clinical Bacteriology, Mycology and Bacterial Diseases are cordially invited for presentation at the conference. (waset.org)
  • ICCBMBD 2020 has teamed up with the Special Journal Issue on Clinical Bacteriology, Mycology and Bacterial Diseases . (waset.org)
  • Novel recombinant toxins are already proposed in the treatment of some diseases, as well as new vaccines. (elsevier.com)
  • In contrast, deaths due to vaccine-preventable diseases are almost entirely due to lack of access to vaccines, not vaccine resistance. (pnas.org)
  • Perhaps you have decided this because of the reports of deaths and serious side effects (seizures, paralysis, Guillain-Barre Syndrome, brain damage, autism, autoimmune diseases, diabetes, cancer, and sudden death) that were linked to various vaccines. (vitalitymagazine.com)
  • Specifically, we will touch on vaccines in development to protect against toxin-mediated diseases. (hstalks.com)
  • He regularly contributes to WHO and EU guidelines, has been an advisor to the International Vaccine Institute's typhoid conjugate vaccine initiative, and serves on the Public Health England invasive bacterial diseases forum. (springer.com)
  • The US Department of Defense has given University of Georgia researchers a 3-year, $1.1 million grant to develop vaccines for glanders and melioidosis, two related diseases caused by strains of the bacterium Burkholderia that are considered potential biological weapons. (umn.edu)
  • The subsequent vaccine organism retains the ability to duplicate and produce immunity , but generally does not cause illness. (omicsonline.org)
  • The recombinant chimpanzee adenovirus type 3-vectored Marburg virus vaccine candidate being tested is aimed at stimulating rapid but durable immunity. (health.mil)
  • Because the flu quickly evolves to escape host immunity, current vaccines tend to be prioritized for inoculating specific high-risk groups such as asthma sufferers and the elderly every year," Arinaminpathy said. (healthcanal.com)
  • At its most effective, the vaccine resulted in strong "herd immunity," or a general resistance to the virus despite only a part of the population receiving the vaccine. (healthcanal.com)
  • He obtained his PhD at St Mary's Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001. (springer.com)
  • This is because the empirical 'clone and test' method of vaccine development has relegated studies of protective immunity and the mode of vaccine action to the back burner. (scidev.net)
  • All these vaccines were developed by cloning and expressing one or several pathogen antigens - immunity-inducing substances - in various vectors. (scidev.net)
  • First, the mechanisms by which vaccine candidates induce protective immunity in the few animals or individuals they protect have not been thoroughly investigated. (scidev.net)
  • This has resulted in a lack of reliable and robust correlates or biomarkers that indicate vaccine-induced protective immunity. (scidev.net)
  • Currently, a GMP-conform production process is being developed and a phase I clinical trial is scheduled for end of 2019/beginning of 2020. (dkfz.de)
  • The vaccine shows better-than-expected effectiveness against the most common and most virulent strain of influenza in children under 9 years old. (the-scientist.com)
  • Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. (medscape.com)
  • H1N1 influenza A presenting as bacterial tracheitis. (medscape.com)
  • Antigenic changes also necessitate frequent updating of influenza vaccine components to ensure that the vaccine is matched to circulating viruses. (cdc.gov)
  • SAN FRANCISCO, May 26 /PRNewswire/ -- Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). (bio-medicine.org)
  • We look forward to continuing our work with government authorities and funding agencies to pursue this very promising vaccine for H1N1 influenza," said Mark Backer, Ph.D., Vaxart CEO. (bio-medicine.org)
  • Vaxart intends to apply its platform to develop a first-in-class vaccine for pandemic influenza, as well as creating oral alternatives to current vaccines such as annual influenza and HPV. (bio-medicine.org)
  • The findings apply not only to Canada but other countries where vaccines were used, and may help guide the further development of influenza vaccine options, the researchers said. (bio-medicine.org)
  • Princeton University-based researchers have found that the "universal" vaccine could for the first time allow for the effective, wide-scale prevention of flu by limiting the influenza virus' ability to spread and mutate. (healthcanal.com)
  • The researchers recently reported in the Proceedings of the National Academy of Sciences that the new vaccines would make a bout with influenza less severe, making it more difficult for the virus to spread. (healthcanal.com)
  • Princeton-based researchers developed a model that revealed that the emerging class of cross-protective, or "universal," vaccines will allow for better flu prevention by limiting the influenza virus' ability to spread and mutate. (healthcanal.com)
  • The percentage of the population infectedwith influenza dropped to zero even though only 70 percent of the population had vaccine protection. (healthcanal.com)
  • In 2006, the world's first human trial of a DNA vaccine against H5N1 avian influenza opened to volunteers. (nih.gov)
  • To update the American Academy of Pediatrics clinical practice guideline regarding the diagnosis and management of acute bacterial sinusitis in children and adolescents. (aappublications.org)
  • If the diagnosis of acute bacterial sinusitis is confirmed in a child with worsening symptoms or failure to improve, then clinicians may change the antibiotic therapy for the child initially managed with antibiotic or initiate antibiotic treatment of the child initially managed with observation. (aappublications.org)
  • Eckel HE, Widemann B, Damm M, Roth B. Airway endoscopy in the diagnosis and treatment of bacterial tracheitis in children. (medscape.com)
  • Disease control relies heavily on the early diagnosis and treatment of the active cases (relevant for anthroponotic disease), although it is widely accepted that a prophylactic vaccine for human leishmaniasis is the way to achieve the successful elimination of human disease (taking in consideration the vast list of non-human reservoirs that enable the perpetuation of parasites all around the globe). (intechopen.com)
  • Assessment of patients with chronic obstructive pulmonary disease (COPD) is important to establish an accurate diagnosis, assist in making therapeutic decisions, measuring outcomes for clinical and research purposes. (omicsonline.org)
  • 7 - 16 Central to our study design has been the microbiologic confirmation of nearly every clinical diagnosis of AOM by culture of middle ear fluid (MEF) collected by tympanocentesis (a technique rarely used worldwide). (aappublications.org)
  • Antimicrobial peptides serve as a part of the innate immune system of respiratory epithelia, potentially reducing bacterial numbers nonspecifically and therefore limiting bacterial colonization ( 9 , 11 , 13 ). (asm.org)
  • Unlike other antibiotics used to treat gonorrhea, zoliflodacin, a spiropyrimidinetrione antimicrobial agent, works by inhibiting DNA biosynthesis by arresting the cleaved covalent gyrase complex, thereby impeding bacterial growth. (clinicaladvisor.com)
  • Vaccines and antimicrobial drugs both impose strong selection for resistance. (pnas.org)
  • Modern medicine and industrial animal farming greatly benefit from vaccines and antimicrobial drugs ( 1 ⇓ - 3 ). (pnas.org)
  • Burkholderia pseudomallei Capsule Exacerbates Respiratory Melioidosis but Does Not Afford Protection against Antimicrobial Signaling or Bacterial Killing in Human Olfactory Ensheathing Cells. (semanticscholar.org)
  • 5 years old to determine invasive pneumococcal disease (IPD) incidence, serotype distribution, clinical presentation, and antimicrobial resistance, which have not been previously described in population-based studies from the region. (ajtmh.org)
  • Clifton L, Ciesielski F, Skoda M, Paracini N, Holt S, Lakey J. The Effect of Lipopolysaccharide Core Oligosaccharide Size on the Electrostatic Binding of Antimicrobial Proteins to Models of the Gram Negative Bacterial Outer Membrane . (ncl.ac.uk)
  • Given these very encouraging new results, PATH is interested in accelerating the development of this promising vaccine/adjuvant for use in infants and young children in low-resource settings. (eurekalert.org)
  • BCG (Bacille Calmette-Guérin), which was developed in 1921 but is still the only licensed vaccine against TB, is used to vaccinate 100 million newborn infants a year. (scidev.net)
  • The leading malaria vaccine candidate, RTS,S/AS01, protected only a third of six- to 12-week-old infants. (scidev.net)
  • The RTS,S/AS01 and MVA85A vaccines targeted young infants. (scidev.net)
  • For the above figure, the researchers simulated the effect of a basic cross-protective vaccine on a flu pandemic based on the proportion of the population that received it. (healthcanal.com)
  • This, however, contains only four strains, ACW and Y). Currently there is no licensed vaccine that is protective against Neisseria meningitidis group X which has caused multiple recent outbreaks in Africa and suggest a hyperendemicity and high capacity for localised epidemics. (google.com)
  • Our vaccine is based on a single molecule, is highly thermostable and more importantly, induces protective responses against all oncogenic HPV as well as a number of so called low risk HPV. (dkfz.de)
  • It was administered in combination with genetically detoxified double-mutant E. coli heat-labile toxin (dmLT) adjuvant, which may enhance the anti-LT response induced by the vaccine and could contribute to protection. (eurekalert.org)
  • We are greatly encouraged by these positive data and hope to see the development of this ETEC vaccine/adjuvant combination continued. (eurekalert.org)
  • PATH is currently in discussion with several developing-country vaccine manufacturers about the ACE527 candidate, and is interested in pursuing other partnership opportunities to conduct further evaluation of the vaccine/adjuvant combination. (eurekalert.org)
  • However, adjuvant recombinant subunit vaccine tied to more injection site adverse events. (clinicaladvisor.com)
  • The National Vaccine Program Office within the U.S. Department of Health and Human Services has responsibility for coordinating and ensuring collaboration among the many federal agencies involved in these efforts. (nih.gov)
  • Recent reports suggest it is a leading cause of bacterial tracheitis and associated with increased intubation. (medscape.com)
  • Heat shock proteins as immunotherapeutic vaccines against cancer: how do they work? (smi-online.co.uk)
  • Parasite proteins could now be produced in unlimited quantities for vaccine research. (scidev.net)
  • The core subject area is the bacterial outer membrane (a nanoscale Hadrian's Wall) but this has spawned projects in natively unfolded proteins (the relaxed guys), bionanotechnology of surfaces (a chance to use physics tricks invented by others), neutron science (a chance to play on seriously big bits of kit) and biopharmaceutical analysis (doing slightly less crazy experiments that are useful to industry at the same time). (ncl.ac.uk)
  • It teaches the immune system to only attack when the proteins on the surface of the bacterial coating break free. (labroots.com)
  • Besides the development of papillomavirus vaccine strategies we are interested to study the functions of the structural proteins L1 and L2 in the course of the viral life cycle. (dkfz.de)
  • Live attenuated vaccines are produced by altering a disease-producing virus or bacterium in a research laboratory. (omicsonline.org)
  • By bringing ten events together under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture. (terrapinn.com)
  • Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. (terrapinn.com)
  • Assessment of patients with COPD for both clinical and research purposes should incorporate a variety of different outcomes. (omicsonline.org)
  • Also, high quality research contributions describing original and unpublished results of conceptual, constructive, empirical, experimental, or theoretical work in all areas of Clinical and Medical Bacteriology are cordially invited for presentation at the conference. (waset.org)
  • The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing. (bio-medicine.org)
  • Our oral vaccine could provide an important tool for swine flu pandemic preparation, because of the speed with which it could be delivered to groups such as first-line medical personnel," said Sean Tucker, Ph.D., Vaxart vice president of research. (bio-medicine.org)
  • The research presents a realistic and important assessment of how the universal vaccines' ability to work against a breadth of flu strains can be wielded to benefit public health, said James Lloyd-Smith, an assistant professor of ecology and evolutionary biology at the University of California-Los Angeles. (healthcanal.com)
  • In doing so, this work provides incentive for the vaccine manufacturers to continue this research and development, and it provides some guidance for public health authorities to think about using these new vaccines once they become available. (healthcanal.com)
  • Local doctors are looking for people with H. Pylori for clinical research studies of an investigational medication. (centerwatch.com)
  • To see if you or your child may qualify to take part in a clinical research study of an investigational eye drop compared to placebo (an inactive substance) - contact a participating local physician. (centerwatch.com)
  • I'm a Senior Vice President at Pfizer, responsible for vaccine research and development. (hstalks.com)
  • The overall result of this program is outstanding preparation for a successful career in pediatric infectious disease within an academic, research or clinical environment. (rchsd.org)
  • Polack directs the INFANT Foundation, a research and clinical institute based in Buenos Aires, in close cooperation with Vanderbilt's Vaccine Center. (eurekalert.org)
  • In the late 1990s, Dr. Ingmar Hoerr, founder and CEO of CureVac GmbH, made an unusual discovery in his doctoral research lab that contradicted the scientific belief at the time that RNA was too unstable for clinical use. (medgadget.com)
  • Because of these talented individuals, today CureVac is a group of 120 dedicated employees, and we continue to advance the research and development and commercial potential of RNA-based vaccines. (medgadget.com)
  • and Clinical Application Research of Beijing (Z131107002213148). (jci.org)
  • NIAID also supports clinical research on vaccines against bacterial, viral, and parasitic microbes in people of all ages and risk categories. (nih.gov)
  • Vaccine safety is an integral component of all NIAID vaccine research and development. (nih.gov)
  • Recently, several National Institutes of Health (NIH) I​nstitutes, including NIAID, have come together to develop a program announcement (PA) to solicit research proposals that broadly address important scientific questions relating to vaccine safety. (nih.gov)
  • For more information on the PA, see Research to Advance Vaccine Safety ( RO1 and R21 ). (nih.gov)
  • In 2000, NIAID established the Dale and Betty Bumpers Vaccine Research Center (VRC). (nih.gov)
  • However, polysaccharides are not highly antigenic, especially in children, so many capsular vaccines contain polysaccharides conjugated with protein carriers, such as the tetanus toxoid or diphtheria toxoid . (wikipedia.org)
  • The Phase 1/2b study results were shared publically for the first time yesterday in an oral presentation by Dr. Clayton Harro of JHU at the 8th Vaccine & ISV Congress in Philadelphia, Pennsylvania. (eurekalert.org)
  • During the 2014 West Africa Ebola outbreak, WRAIR conceived of, and then initiated a Phase I clinical trial of the VSV-EBOV vaccine candidate over a period of just 11 weeks at its CTC. (health.mil)
  • We now entered into a clinical development phase. (dkfz.de)
  • In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live bi. (bioportfolio.com)
  • was the most common form in children before the introduction of the Hib vaccine in 1992, but since then has been virtually eliminated. (netdoctor.co.uk)
  • This cause is less common since the introduction of the Hib vaccine. (medscape.com)
  • Although the apparent window of safety is narrow, SC602 is the first example of an attenuated S. flexneri 2a candidate vaccine that provides protection against shigellosis in a stringent, human challenge model. (asm.org)
  • In the absence of a definitive immunologic correlate of protection against shigellosis, promising Shigella vaccine candidates have been selected based on their ability to confer resistance against experimental challenge with wild-type Shigella in healthy adult volunteers. (nih.gov)
  • He is the co-inventor of a rotavirus vaccine that has been credited with saving hundreds of lives every day. (terrapinn.com)
  • The intervention evaluated was a single dose of PCV13 compared to a dose of 23-valent polysaccharide vaccine (PPSV23). (cdc.gov)
  • The guideline is intended for use in a variety of clinical settings (eg, office, emergency department, hospital) by clinicians who treat pediatric patients. (aappublications.org)
  • Obtain bacterial culture and Gram stain of tracheal secretions and blood cultures in patients with suspected bacterial tracheitis. (medscape.com)
  • Patients with bacterial keratitis usually complain of rapid onset of pain, photophobia, and decreased vision. (medscape.com)
  • Of patients with bacterial keratitis, 19-42% are contact lens wearers. (medscape.com)
  • At Mass General, the brightest minds in medicine collaborate on behalf of our patients to bridge innovation science with state-of-the-art clinical medicine. (massgeneral.org)
  • Patients have been reported to present with symptoms and signs of bacterial tracheitis and multiorgan failure due to exotoxin-producing strains of Staphylococcus aureus or Streptococcus pyogenes in the trachea. (medscape.com)
  • Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant. (centerwatch.com)
  • Patients' demographic and clinical profiles are shown in Technical Appendix Table 1. (cdc.gov)
  • Please see the list below for VCA veterinary clinical studies enrolling patients at this time. (vcahospitals.com)
  • A stage 1 study established that this combinatory gmDC vaccine is safe in acute leukemia patients and yielded improved survival rate. (jci.org)
  • This narrative review outlines the current knowledge regarding E. histolytica and E. dispar and insight in the development of a vaccine. (hindawi.com)